Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TELA Bio, Inc. (NASDAQ: TELA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its filings offer detailed information on financial performance, capital structure, governance, and material agreements that affect TELA stock.
Investors can review current reports on Form 8-K, where TELA Bio reports material events such as entry into significant credit agreements, registered direct offerings of common stock and pre-funded warrants, and changes in directors and compensatory arrangements. For example, the company has filed 8-Ks describing a senior secured term loan facility with Perceptive Credit Holdings V, LP, the terms of associated warrants to purchase common stock, and the termination of a prior credit and security agreement. Other 8-Ks furnish press releases announcing quarterly financial results and updated investor presentations.
Through its periodic reports (10-K and 10-Q, accessible via EDGAR and summarized on this page), users can analyze TELA Bio’s revenue, gross profit, operating expenses, and net loss, as well as balance sheet items such as cash, long-term debt, and stockholders’ equity. These filings also contain risk factor discussions covering macroeconomic conditions, surgical procedure volumes, competition, product development and manufacturing issues, and reimbursement considerations.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major changes in revenue trends, liquidity, debt covenants, and equity offerings. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and related exhibits appear promptly, while insider and equity-related disclosures such as warrant issuances and director equity awards can be examined alongside the underlying text.
For anyone researching TELA Bio’s regulatory history, financing arrangements, and board-level changes, this filings page offers a structured view of the company’s official disclosures with AI assistance to interpret complex legal and financial language.
TELA Bio, Inc. director and CEO Antony Koblish reported a mix of equity awards and tax-related share dispositions. On February 20, 2026, he was granted 176,000 shares of common stock as restricted stock units that will vest in four equal annual installments beginning on February 20, 2027, subject to his continued service. He also received a stock option for 261,000 shares, vesting 25% on February 20, 2027 and the remaining 75% in equal monthly installments over the following 36 months, also subject to continued service. On February 21, 23, and 24, 2026, a total of 28,?? shares of common stock were disposed of at prices between $0.7174 and $0.7852 per share to cover withholding taxes upon RSU vesting, with shares withheld by the issuer rather than sold in open-market transactions.
TELA Bio, Inc. Chief Business Officer Gregory A. Firestone reported a mix of equity grants and tax-related share dispositions. On February 20, 2026, he was granted 55,000 stock options and 37,000 shares of common stock in the form of restricted stock units that vest in four equal annual installments beginning February 20, 2027, subject to his continued service. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, also conditioned on continued service. On February 21 and 23, 2026, a total of 5,541 common shares were withheld by the company at prices of
TELA Bio, Inc. reported several equity transactions by Chief Technology Officer Paul Talmo. On February 20, 2026, he received awards of 57,000 shares of common stock and 85,000 stock options, each at a grant price of $0.00 per share.
The stock award consists of restricted stock units that vest in four equal annual installments beginning on February 20, 2027, subject to continuous service. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months.
On February 21 and 23, 2026, the company withheld 3,385 and 4,061 shares of common stock, respectively, at prices of $0.7174 and $0.766 per share to cover tax liabilities upon RSU vesting. After these transactions, Talmo directly held 173,436 shares of common stock and 85,000 stock options.
TELA Bio, Inc. executive Roberto Cuca, the COO and CFO, reported a mix of equity awards and tax-related share withholdings. On February 20, 2026, he received a grant of 85,000 stock options and an award of 57,000 shares of common stock, both as direct ownership. The options vest over four years starting February 20, 2027, and the share award consists of RSUs vesting in four equal annual installments beginning the same date, subject to continued service.
To cover withholding taxes on RSU vesting, the issuer withheld 4,780 shares on February 21, 2026 at $0.7174 per share and 5,234 shares on February 23, 2026 at $0.7660 per share, characterized as tax-withholding dispositions rather than open-market sales. After these transactions, Cuca directly owned 257,377 shares of common stock.
TELA Bio, Inc. President Jeffrey Blizard reported equity awards consisting of stock options and restricted stock units granted on February 20, 2026. He was granted stock options for 127,000 shares at an exercise price of $0.00 per share and a separate award of 86,000 shares of common stock in the form of restricted stock units.
The restricted stock units will vest in four equal annual installments beginning on February 20, 2027, contingent on his continuous service through each vesting date. The stock option will vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, also subject to continued service.
TELA Bio, Inc. Chief Accounting Officer Megan Smeykal reported multiple equity transactions involving the company’s common stock. On February 18, 2026, she acquired 32,850 shares through a grant of restricted stock units (RSUs) at a stated price of $0.0000 per share. According to the footnotes, these RSUs vest in four equal annual installments beginning on February 18, 2027, contingent on her continued service.
On February 19, 21, and 23, 2026, shares of common stock were disposed of in three separate transactions coded “F,” each described as a tax-withholding disposition to satisfy withholding taxes upon RSU vesting. After the latest transaction, her direct holdings stood at 66,873 shares of common stock.
TELA Bio is registering up to 2,000,000 shares of common stock for resale by Perceptive Credit Holdings V, LP, issuable upon exercise of a warrant connected to a November 2025 credit agreement. These shares may be sold from time to time on Nasdaq or in private transactions at market or negotiated prices, with the selling stockholder paying its own selling commissions while TELA covers registration expenses. TELA will not receive proceeds from any resale of these shares, but could receive cash if the warrant is exercised, which it currently plans to use for general corporate purposes such as sales and marketing, research and development, working capital and capital spending.
TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction, led by its OviTex hernia repair and OviTex PRS plastic and reconstructive surgery product portfolios. The company cites an estimated U.S. addressable market of about $1.8 billion for OviTex and $800 million for OviTex PRS. A key risk highlighted is that future sales of these registered shares by the selling stockholder, or the perception that such sales may occur, could put downward pressure on TELA’s stock price.
TELA Bio, Inc. reported an insider share purchase by major holders connected to EW Healthcare Partners. On 11/17/2025, these reporting persons acquired 3,604,000 shares of TELA Bio common stock in the company’s underwritten registered direct offering at a price of $1.11 per share. After this transaction, they beneficially own a total of 7,714,709 shares, split between EW Healthcare Partners Fund 2, L.P. and EW Healthcare Partners Fund 2-A, L.P. The filing notes that control over voting and investment decisions for these shares is held through the EW Healthcare general partner structure and its managers, who each disclaim ownership beyond their pecuniary interests.
TELA Bio entered a senior secured term loan with Perceptive for up to $70.0 million. An initial $60.0 million will fund on November 14, 2025, with an additional $10.0 million delayed draw available subject to conditions. The facility matures on November 14, 2030, bears interest at 7.85% plus the greater of the Reference Rate or 4.25% (minimum 12.10% per annum), has no scheduled amortization, and includes prepayment premiums of 2%–10%. Obligations are secured by a first‑lien on substantially all assets.
As consideration, TELA will issue warrants to purchase up to 2,000,000 shares at $1.11 on closing and up to 333,333 shares at $1.11 if the delayed draw is funded; the warrants expire on November 14, 2035 and permit cashless exercise and resale registration rights. A post‑closing condition requires evidence by November 17, 2025 of at least $8,500,000 in gross proceeds from a registered direct offering.
Separately, TELA launched an underwritten registered direct offering of 4,189,000 shares at $1.11 and 7,523,000 pre‑funded warrants at $1.1099, for expected net proceeds of about $11.9 million. Pre‑funded warrants are immediately exercisable at $0.0001 with a 9.99% (or 4.99%) beneficial ownership cap. The prior MidCap facility was terminated and its lien released.
TELA Bio, Inc. filed its quarterly report, showing higher sales and a narrower loss. Revenue for Q3 2025 reached $20.7 million, up 9% from $19.0 million a year ago, with gross margin steady at 68%. The company reported a net loss of $8.6 million for the quarter, an improvement from a $10.4 million loss in Q3 2024. For the first nine months of 2025, revenue was $59.4 million versus $51.7 million in 2024, while net loss was $29.8 million compared to $28.6 million, which included a prior-year gain on a product line sale.
Cash and cash equivalents were $29.7 million as of September 30, 2025, down from $52.7 million at year-end, driven by operating cash outflows of $23.3 million year‑to‑date. Long-term debt was $41.5 million. Subsequent to quarter‑end, TELA closed a new credit facility of up to $70.0 million with Perceptive, including an initial $60.0 million draw used in part to repay its MidCap loan; the facility bears interest at 7.85% plus the greater of one‑month Term SOFR or 4.25% and is interest‑only until November 14, 2030. The company also entered an underwriting agreement for an underwritten registered direct offering of 4,189,000 shares at $1.11 per share and pre‑funded warrants for 7,523,000 shares at $1.1099 per warrant, for expected gross proceeds of approximately $13.0 million, subject to customary closing conditions.